Plain-English translation of NCT07039149 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing the timing of dual antiplatelet therapy (blood-thinning medications) for patients having a heart attack in the emergency department. Doctors know that aspirin should be given right away, but the study is comparing whether giving a second blood-thinning medication immediately in the emergency department is safer and more effective than waiting to give it in the catheterization lab (the procedure room where doctors look at your heart's blood vessels).
Current treatment guidelines from Western hospitals recommend waiting until the catheterization lab to give the second medication, to reduce bleeding risks. However, this trial's doctors believe that patients in the Middle East may have different health profiles and lower bleeding risk, so giving both medications earlier in the emergency department might be beneficial without causing more bleeding complications.
You likely qualify if…
You likely don't qualify if…
You will receive aspirin immediately when you arrive at the emergency department, which is standard care. Your doctor will decide whether to give you a second blood-thinning medication right away in the emergency department or wait until you go to the catheterization lab. Either way, doctors will monitor you for any serious bleeding or heart complications. You will be called for follow-up check-ins over the next year to see how well you recovered.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Jordan
Sponsor
Jordan Collaborating Cardiology Group
Enrollment target
~200 participants
Started
August 2025
Primary completion
August 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ayman Hammoudeh, MD, FACC
Jordan Collaborating Cardiology Group
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.